Ian E. Krop
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 224
- HER2/EGFR in Cancer Research 151
- Cancer Treatment and Pharmacology 87
-
- Advanced Breast Cancer Therapies 78
- Lung Cancer Treatments and Mutations 24
- Co-authors
- Eric P. Winer (111 shared papers)Véronique Dièras (15 shared papers)David Miles (6 shared papers)Manfred Welslau (4 shared papers)Sunil Verma (13 shared papers)Ellie Guardino (8 shared papers)Mark D. Pegram (11 shared papers)Luca Gianni (9 shared papers)
- Journals
- Journal of Clinical Oncology (115 papers)Cancer Research (48 papers)Annals of Oncology (25 papers)Clinical Cancer Research (13 papers)Breast Cancer Research and Treatment (10 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Ian E. Krop
292 papers receiving 19.2k citations
Ian E. Krop's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 12.1k
- Cancer Research 3.1k
- Radiology, Nuclear Medicine and Imaging 4.4k
- Pulmonary and Respiratory Medicine 4.4k
- Genetics 1.2k
Countries citing papers authored by Ian E. Krop
This map shows the geographic impact of Ian E. Krop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian E. Krop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian E. Krop more than expected).
Fields of papers citing papers by Ian E. Krop
This network shows the impact of papers produced by Ian E. Krop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian E. Krop. The network helps show where Ian E. Krop may publish in the future.
Co-authors
The 25 scholars most cited alongside Ian E. Krop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 301 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 2724 |
| 2 | CDK4/6 inhibition triggers anti-tumour immunity Hit paper breakdown → | 2017 | 1033 |
| 3 | Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens Hit paper breakdown → | 2017 | 804 |
| 4 | Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy Hit paper breakdown → | 2010 | 576 |
| 5 | Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study Hit paper breakdown → | 2020 | 565 |
| 6 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 516 |
| 7 | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 477 |
| 8 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer Hit paper breakdown → | 2015 | 464 |
| 9 | 2010 | 440 | |
| 10 | Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial Hit paper breakdown → | 2017 | 377 |
| 11 | 2017 | 294 | |
| 12 | 2014 | 290 | |
| 13 | 2012 | 279 | |
| 14 | 2015 | 273 | |
| 15 | 2019 | 261 | |
| 16 | Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors Hit paper breakdown → | 2020 | 260 |
| 17 | 2014 | 259 | |
| 18 | 2012 | 255 | |
| 19 | 2016 | 223 | |
| 20 | 2013 | 212 |
About Ian E. Krop
Ian E. Krop is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 301 papers that have together received 19.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (151 papers), Cancer Treatment and Pharmacology (87 papers), Advanced Breast Cancer Therapies (78 papers), Breast Cancer Treatment Studies (57 papers), Monoclonal and Polyclonal Antibodies Research (39 papers), Cancer Genomics and Diagnostics (30 papers), PI3K/AKT/mTOR signaling in cancer (24 papers) and Lung Cancer Treatments and Mutations (24 papers). The work is most often cited by research in Oncology (12.1k citations), Cancer Research (3.1k citations), Radiology, Nuclear Medicine and Imaging (4.4k citations), Pulmonary and Respiratory Medicine (4.4k citations) and Genetics (1.2k citations). Ian E. Krop has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Eric P. Winer, Véronique Dièras, David Miles, Manfred Welslau, Sunil Verma, Ellie Guardino, Mark D. Pegram, Luca Gianni, Kim T. Blackwell and Michael W. Lu. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Clinical Cancer Research and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.